Companies › Nouscom SRL
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GAd20-209-FSP Genetic vaccine encoding frameshift peptides (FSP) from mismatch repair-deficient tumors | – | Phase 1 | Solid Tumor, Adult | – |
| MVA-209-FSP Genetic vaccine encoding frameshift peptides (FSP) from mismatch repair-deficient tumors | – | Phase 1 | Solid Tumor, Adult | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04041310 | GAd20-209-FSP | Phase 1 | Solid Tumor, Adult | Oncology | Oct 2026 |
| NCT04041310 | MVA-209-FSP | Phase 1 | Solid Tumor, Adult | Oncology | Oct 2026 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.